



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

CytoDyn to Hold Webcast on December 10 to Update Clinical and Regulatory Developments

Dec 3 2020, 2:35 PM EST

CytoDyn Announces First Patient Enrolled in Phase 2 Trial for NASH

Dec 2 2020, 6:00 AM EST

CytoDyn Announces Partnership with amfAR to Accelerate HIV Cure Research

Nov 23 2020, 4:16 PM EST

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	1.4b
Last Price	\$2.45
52-Week Range	\$0.26 - \$10.01

12/03/2020 03:59 PM EST

Management Team

Nader Z. Pourhassan, Ph.D.

Director, President and CEO

Scott A. Kelly, M.D.

Chief Medical Officer, Head of Business Development and Chairman of the Board

Nitya G. Ray, Ph.D.

Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Michael D. Mulholland

Chief Financial Officer

Brian Brothen

Senior Vice President, Global Oncology

Mahboob U. Rahman, M.D., Ph.D., FACR

Chief Scientific Officer

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.